Stemline Therapeutics Inc. (STML) Upgraded to Buy by Zacks Investment Research
Zacks Investment Research upgraded shares of Stemline Therapeutics Inc. (NASDAQ:STML) from a hold rating to a buy rating in a research note issued to investors on Wednesday. They currently have $12.00 price target on the biopharmaceutical company’s stock.
According to Zacks, “Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. “
A number of other equities analysts have also recently issued reports on STML. Wedbush reiterated an outperform rating and issued a $16.00 target price on shares of Stemline Therapeutics in a report on Tuesday, June 7th. Jefferies Group restated a buy rating and set a $23.00 price objective on shares of Stemline Therapeutics in a research note on Friday, July 22nd. Finally, Roth Capital restated a buy rating and set a $32.00 price objective on shares of Stemline Therapeutics in a research note on Thursday, June 9th. Six analysts have rated the stock with a buy rating, The stock presently has a consensus rating of Buy and a consensus target price of $20.50.
Shares of Stemline Therapeutics (NASDAQ:STML) traded down 1.80% during midday trading on Wednesday, hitting $10.89. 73,712 shares of the stock were exchanged. Stemline Therapeutics has a 1-year low of $3.88 and a 1-year high of $11.29. The firm’s market capitalization is $194.11 million. The stock’s 50-day moving average price is $9.17 and its 200-day moving average price is $7.15.
Stemline Therapeutics (NASDAQ:STML) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.03. Stemline Therapeutics had a negative return on equity of 44.59% and a negative net margin of 4,419.18%. On average, analysts forecast that Stemline Therapeutics will post ($2.11) EPS for the current year.
Several large investors have recently made changes to their positions in the stock. Emerald Acquisition Ltd. acquired a new stake in shares of Stemline Therapeutics during the second quarter valued at about $129,000. Paradigm Asset Management Co. LLC acquired a new stake in shares of Stemline Therapeutics during the second quarter valued at about $141,000. Nationwide Fund Advisors raised its stake in shares of Stemline Therapeutics by 63.2% in the second quarter. Nationwide Fund Advisors now owns 22,395 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 8,670 shares in the last quarter. Carl Domino Inc raised its stake in shares of Stemline Therapeutics by 12.9% in the second quarter. Carl Domino Inc now owns 26,305 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 3,000 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in shares of Stemline Therapeutics by 20.9% in the second quarter. Rhumbline Advisers now owns 26,260 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 4,538 shares in the last quarter. 52.42% of the stock is owned by hedge funds and other institutional investors.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Stock Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related stocks with our FREE daily email newsletter.